Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Gross Margin (2023 - 2025)

ImmunityBio (IBRX) has disclosed Gross Margin for 3 consecutive years, with 99.0% as the latest value for Q4 2025.

  • On a quarterly basis, Gross Margin fell 100.0% to 99.0% in Q4 2025 year-over-year; TTM through Dec 2025 was 99.34%, a 66.0% decrease, with the full-year FY2025 number at 99.34%, down 66.0% from a year prior.
  • Gross Margin was 99.0% for Q4 2025 at ImmunityBio, roughly flat from 99.45% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 100.0% in Q2 2023 to a low of 99.0% in Q4 2025.
  • A 3-year average of 99.76% and a median of 100.0% in 2023 define the central range for Gross Margin.
  • Peak YoY movement for Gross Margin: changed 0bps in 2024, then plummeted -100bps in 2025.
  • ImmunityBio's Gross Margin stood at 100.0% in 2023, then changed by 0bps to 100.0% in 2024, then decreased by -1bps to 99.0% in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Gross Margin are 99.0% (Q4 2025), 99.45% (Q3 2025), and 99.49% (Q2 2025).